Aptar Pharma Recognises World Parkinson's Day with a New White Paper Focused on Blood-Brain Barrier Drug Delivery
![](/46/pdcnewsitem/03/43/63/dXzHH0YsLXk4mjl.jpg)
Aptar Pharma presents a new scientific white paper, following its recent roundtable held in Paris, France.
The goal of this roundtable was to explore and exchange views on the challenges, approaches and opportunities that exist with regard to effectively crossing the blood-brain barrier (BBB) and successfully treating a host of central nervous system (CNS) diseases. The CNS, which comprises the brain, spinal cord and a complex system of neurons, integrates and responds to sensory information, playing a key role by coordinating body function. Diseases such Parkinson’s and Alzheimer’s are CNS disorders that affect a growing population.
Although many molecules can be used to treat brain and more generally, CNS diseases, today, only 1% of these molecules can cross the BBB, a “firewall” that allows the passage of oxygen and nutrients but blocks the entrance of what it considers harmful or toxic molecules into the brain. The challenge therefore lies in identifying potential routes for drug delivery, hence the title of the roundtable: “Crossing the Blood-Brain Barrier, Which Route to Take?”
Aptar Pharma’s scientific roundtable brought together a panel of six eminent international key opinion leaders (KOLs) specialized in brain and CNS therapies:
• Prof. Alexandre Carpentier, PhD and Scientific Consultant, Hôpital Pitié-
Salpetrière & Carthera, France
• Prof. Margareta Hammarlund-Udenaes, Head, Translational PKPD Group,
Uppsala University & Udenaes Consulting, Sweden
• Prof. Kewal Jain, Scientific Consultant, Jain Pharmabiotech, Switzerland
• Dr Jaap Rip, Senior Scientist, BBB Therapeutics, the Netherlands
• Dr Frédéric Sedel, CEO, Medday Pharma, France
• Dr Jasper Stevens, Pharmacometrician, Centre for Human Drug Research, Leiden, the Netherlands.
During this one-day meeting, these scientific experts shared their knowledge and debated several key themes, structured around the following:
• Understanding the background and unmet medical needs
• Investigating the various delivery routes via which drugs can cross the BBB
• Exploring the pros and cons of various approaches currently adopted to delivery drugs to the CNS.
In addition, the KOLs discussed various possible approaches to deliver drugs to the CNS or brain, both conventional and innovative, including the use of receptor technologies, implantable medical devices and nose to brain (N2B) drug transport.
Based on the discussions and input from participants, Aptar Pharma prepared a scientific publication entitled “Crossing the Blood-Brain Barrier, Which Route to Take?”
“All of the experts at our scientific roundtable confirmed the fact that delivering drugs safely and efficaciously to the brain and CNS remains a challenge. In fact, a major unmet medical need exists, and the market offers very attractive opportunities for drug delivery solutions that guarantee safety and efficacy, and are patient and caregiver-friendly,” said Hervé Pacaud, Business Development Director, Aptar Pharma Prescription Division.
He concluded: “By organizing this scientific event, and with the input from the KOLs, Aptar Pharma has identified this unmet medical need and determined ways to optimize treatments for patients.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance